Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks

被引:62
作者
Bailly, C
Lansiaux, A
Dassonneville, L
Demarquay, D
Coulomb, H
Huchet, M
Lavergne, O
Bigg, DCH
机构
[1] IRCL, Ctr Oscar Lambert, INSERM U524, F-59045 Lille, France
[2] IRCL, Ctr Oscar Lambert, Lab Pharmacol Antitumorale, F-59045 Lille, France
[3] Inst Henri Beaufour, F-91966 Les Ulis, France
关键词
D O I
10.1021/bi990947h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Homocamptothecin (hCPT) contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone ring found in camptothecin and its tumor active analogues, including topotecan and irinotecan. The homologation of the lactone E-ring reinforces the stability of the lactone, thus reducing considerably its conversion into a carboxylate form which is inactive. We have recently shown that hCPT is much more active than the parent compound against a variety of tumor cells in vitro and in xenograft models, suggesting that a highly reactive lactone is not essential for topoisomerase I-mediated anticancer activity [Lesueur-Ginot et al. (1999) Cancer Res. 59, 2939-2943]. In the present study, we provide further evidence that hCPT has superior topoisomerase I inhibition capacities to CPT. In particular, we show that replacement of the camptothecin lactone E-ring with a homologous seven-membered lactone ring changes the sequence-specificity of the drug-induced DNA cleavage by topoisomerase I. Both CPT and hCPT stimulate the cleavage by topoisomerase I at T(down arrow)G sites, but in addition, hCPT stabilizes cleavage at specific sites containing the sequence AAC(down arrow)G. At low drug concentrations, the cleavage at the Tic sites and at the hCPT-specific C(down arrow)G sites is more pronounced and more stable with hCPT than with CPT. The in vitro data were confirmed in cells. Higher levels of protein-DNA complexes were detected in P388 leukemia cells treated with hCPT than those treated with CPT. Immunoblotting experiments revealed that endogenous topoisomerase I was efficiently trapped onto DNA by hCPT in cells. Finally, the use of a leukemia cell line resistant to CPT provided evidence that topoisomerase I is involved in the cytotoxicity of hCPT. Altogether, the results show that the beta-hydroxylactone ring of hCPT plays an important and positive role in the poisoning of topoisomerase I. An explanation is proposed to account for such remarkable changes in the sequence specificity of topoisomerase I cleavage consequent to the modification of the lactone. The study sheds new light on the importance of the lactone ring of camptothecins for the stabilization of topoisomerase I-DNA complexes.
引用
收藏
页码:15556 / 15563
页数:8
相关论文
共 28 条
[1]  
Abang AM, 1998, SEMIN HEMATOL, V35, P13
[2]   Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA [J].
Chourpa, I ;
Riou, JF ;
Millot, JM ;
Pommier, Y ;
Manfait, M .
BIOCHEMISTRY, 1998, 37 (20) :7284-7291
[3]   Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin [J].
Fan, Y ;
Weinstein, JN ;
Kohn, KW ;
Shi, LM ;
Pommier, Y .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) :2216-2226
[4]  
HSIANG YH, 1985, J BIOL CHEM, V260, P4873
[5]  
JAXEL C, 1991, J BIOL CHEM, V266, P20418
[6]   THE ANTILEUKEMIC ALKALOID FAGARONINE IS AN INHIBITOR OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II [J].
LARSEN, AK ;
GRONDARD, L ;
COUPRIE, J ;
DESOIZE, B ;
COMOE, L ;
JARDILLIER, JC ;
RIOU, JF .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (08) :1403-1412
[7]   BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities [J].
Lavergne, O ;
LesueurGinot, L ;
Rodas, FP ;
Bigg, DCH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (17) :2235-2238
[8]   Homocamptothecins:: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues [J].
Lavergne, O ;
Lesueur-Ginot, L ;
Rodas, FP ;
Kasprzyk, PG ;
Pommier, J ;
Demarquay, D ;
Prévost, G ;
Ulibarri, G ;
Rolland, A ;
Schiano-Liberatore, AM ;
Harnett, J ;
Pons, D ;
Camara, J ;
Bigg, DCH .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (27) :5410-5419
[9]  
Lesueur-Ginot L, 1999, CANCER RES, V59, P2939
[10]   SYNTHESIS AND ANTITUMOR-ACTIVITY OF NOVEL WATER-SOLUBLE DERIVATIVES OF CAMPTOTHECIN AS SPECIFIC INHIBITORS OF TOPOISOMERASE-I [J].
LUZZIO, MJ ;
BESTERMAN, JM ;
EMERSON, DL ;
EVANS, MG ;
LACKEY, K ;
LEITNER, PL ;
MCINTYRE, G ;
MORTON, B ;
MYERS, PL ;
PEEL, M ;
SISCO, JM ;
STERNBACH, DD ;
TONG, WQ ;
TRUESDALE, A ;
UEHLING, DE ;
VUONG, A ;
YATES, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (03) :395-401